Thrombopoietin receptor activation, thrombopoietin mimetic drugs, and hereditary thrombocytosis: Remarks on bone marrow fibrosis

Journal of Clinical Oncology

Volumn 28, Issue 19, 2010, Pages

  Teofili, Luciana ^a   Giona, Fiorina ^b   Martini, Maurizio ^a   Torti, Lorenza ^a   Cenci, Tonia ^a   Foà, Robin ^b   Leone, Giuseppe ^a   Larocca, Luigi M ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ELTROMBOPAG; HEMOGLOBIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; ROMIPLOSTIM; STAT5 PROTEIN; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR; BENZOIC ACID DERIVATIVE; FC RECEPTOR; HYBRID PROTEIN; HYDRAZINE DERIVATIVE; PYRAZOLE DERIVATIVE;

AGING; BINDING SITE; DISEASE COURSE; GENE MUTATION; HUMAN; LETTER; LIFE EXPECTANCY; MYELOFIBROSIS; PRIORITY JOURNAL; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; SPLENOMEGALY; THROMBOCYTOSIS; THROMBOSIS; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG POTENTIATION; GENETICS; METABOLISM; MUTATION; MYELOID METAPLASIA; THROMBOCYTOPENIA; TRANSCRIPTION INITIATION;

BENZOIC ACIDS; HUMANS; HYDRAZINES; MUTATION; PRIMARY MYELOFIBROSIS; PYRAZOLES; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; THROMBOCYTOPENIA; THROMBOCYTOSIS; THROMBOPOIETIN; TRANSCRIPTIONAL ACTIVATION;

EID: 77955495245     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.29.0387     Document Type: Letter

References (19)

1. Wiestner A, Schlemper RJ, van der Maas AP, et al: An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia. Nat Genet 18:49-52, 1998 (Pubitemid 28027878)
2. Ghilardi N, Wiestner A, Skoda RC: Thrombopoietin production is inhibited by a translational mechanism. Blood 92:4023-4030, 1998 (Pubitemid 28544314)
3. Kondo T, Okabe M, Sanada M, et al: Familial essential thrombocythemia associated with one-base deletion in the 5′-untranslated region of the thrombopoietin gene. Blood 92:1091-1096, 1998 (Pubitemid 28369020)
4. Ghilardi N, Wiestner A, Kikuchi M, et al: Hereditary thrombocythaemia in a Japanese family is caused by a novel point mutation in the thrombopoietin gene. Br J Haematol 107:310-316, 1999 (Pubitemid 29530216)
5. Liu K, Kralovics R, Rudzki Z, et al: A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish family. Haematologica 93:706-714, 2008 (Pubitemid 351669310)
6. Ghilardi N, Skoda RC: A single-base deletion in the thrombopoietin (TPO) gene causes familial essential thrombocythemia through a mechanism of more efficient translation of TPO mRNA. Blood 94:1480-1482, 1999 (Pubitemid 29380432)
7. Moliterno AR, Williams DM, Gutierrez-Alamillo LI, et al: Mpl Baltimore: A thrombopoietin receptor polymorphism associated with thrombocytosis. Proc Natl Acad Sci U S A 101:11444-11447, 2004 (Pubitemid 39038366)
8. El-Harith el-HA, Roesl C, Ballmaier M, et al: Familial thrombocytosis caused by the novel germ-line mutation p.Pro106Leu in the MPL gene. Br J Haematol 44:185-194, 2009
9. Ding J, Komatsu H, Wakita A, et al: Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 103:4198-4200, 2004 (Pubitemid 38685363)
10. Teofili L, Giona F, Martini M, et al: Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. J Clin Oncol 25:1048-1052, 2007
11. Teofili L, Giona F, Torti L, et al: MPLSer505Asn induced hereditary thrombocytosis is associated with a high thrombotic risk, splenomegaly, and progression to bone marrow fibrosis. Haematologica 95:65-70, 2010
12. Kuter DJ: New thrombopoietic growth factors. Blood 109:4607-4616, 2007
13. Kuter DJ, Bussel JB, Lyons RM, et al: Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double-blind randomised controlled trial. Lancet 371:395-403, 2008 (Pubitemid 351181334)
14. Bussel JB, Kuter DJ, Pullarkat V, et al: Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 113:2161-2171, 2009
15. Kuter DJ, Mufti GJ, Bain BJ, et al: Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood 114:3748-3756, 2009
16. Bussel JB, Provan D, Shamsi T, et al: Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: A randomised, double-blind, placebo-controlled trial. Lancet 373:641-648, 2009
17. Kantarjian H, Fenaux P, Sekeres MA, et al: Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol 28:437-444, 2010
18. Pecquet C, Staerk J, Chaligné R, et al: Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor. Blood 115:1037-1048, 2010
19. Della Porta MG, Malcovati L, Boveri E, et al: Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol 27:754-762, 2009